title: Migraine-associated vertigo: clinical characteristics of Japanese patients and effect of lomerizine, a calcium channel antagonist.
abstract: CONCLUSIONS
  Lomerizine, a calcium channel blocker, may be effective as a treatment for migraine-associated vertigo (MAV). Objective. To determine the clinical characteristics of patients with MAV in Japan and the effectiveness of lomerizine.
  
  
  METHODS
  This was a retrospective chart review carried out in a university hospital of 33 patients who fulfilled the diagnostic criteria for MAV. All patients were initially treated with dietary manipulation. If this therapy was unsuccessful, oral medications, mainly lomerizine, were administered. Medical records were reviewed to find clinical characteristics of patients with MAV and to evaluate the effects of the therapy on vertigo/dizziness symptoms.
  
  
  RESULTS
  A marked female predominance was found (23 women, 10 men). The frequency and the duration of vertigo varied across patients. About 60% of the patients had cochlear symptoms during an attack, among which bilateral aural fullness was most frequent. Oto-neurological examination showed abnormalities in 33% of the patients. Overall, 27 of the 33 patients (82%) responded to our therapy. Among the 22 patients who were prescribed lomerizine, 19 patients (87%) showed resolution or significant improvement of the symptoms.
authors.affiliation: Department of Otolaryngology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. iwashin-tky@umin.ac.jp
authors.forename: Shinichi
authors.initials: S
authors.lastname: Iwasaki
authors.forename: Munetaka
authors.initials: M
authors.lastname: Ushio
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Chihara
authors.forename: Ken
authors.initials: K
authors.lastname: Ito
authors.forename: Keiko
authors.initials: K
authors.lastname: Sugasawa
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Murofushi
mesh_terms: D000293:Adolescent; D000328:Adult; D044466:Asian People; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005071:Evoked Potentials / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications*; D009759:Nystagmus, Pathologic / Q000209:etiology; D010879:Piperazines / Q000627:therapeutic use*; D014717:Vertigo / Q000188:drug therapy* / Q000209:etiology*; D014722:Vestibule, Labyrinth / Q000502:physiology*
chemical_list: D002121:Calcium Channel Blockers; D010879:Piperazines; C052424:lomerizine